The latest EU nod makes Roche's (RHHBY) immuno-oncology drug — Tecentriq — the first and only cancer immunotherapy approved for the initial treatment of ES-SCLC in Europe.
source https://finance.yahoo.com/news/roches-tecentriq-combo-gets-eu-123912355.html?.tsrc=rss
blaineonline.finance.blog 